Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

2 Dividend Kings to Buy on the Dip and Hold Forever: https://g.foolcdn.com/editorial/images/747350/doctor-and-patient-in-a-hospital-room.jpg
2 Dividend Kings to Buy on the Dip and Hold Forever

The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
3 Top Healthcare Stocks Defying the Bear Market: https://g.foolcdn.com/editorial/images/747505/dnaphoto.jpg
3 Top Healthcare Stocks Defying the Bear Market

Healthcare stocks, often considered recession-proof, have lagged most other sectors of the market so far this year. While the S&P 500 index is up by more than 16% and flirting with a return to bull

Could Abbott Laboratories Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/747360/two-couples-on-a-yacht.jpg
Could Abbott Laboratories Stock Help You Become a Millionaire?

Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. It has a diverse business with four key segments: established pharmaceuticals, diagnostics, nutrition, and

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday: https://g.foolcdn.com/editorial/images/747734/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech's shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target

Why Shares of Iovance Biotherapeutics Dropped Thursday: https://g.foolcdn.com/editorial/images/747719/radiologist-of-oncology-institute-is-examing-mri-scans.jpg
Why Shares of Iovance Biotherapeutics Dropped Thursday

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell more than 13% on Thursday. The biotech company, which specializes in using tumor-infiltrating lymphocyte (TIL) therapies to fight cancer, has

Cathie Wood Is Betting on This Struggling Stock. Should You?: https://g.foolcdn.com/editorial/images/747553/gettyimages-1203044156.jpg
Cathie Wood Is Betting on This Struggling Stock. Should You?

Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has

Why AT&T Stock Was Moving Higher Today: https://g.foolcdn.com/editorial/images/747654/att-5g.jpg
Why AT&T Stock Was Moving Higher Today

Shares of AT&T (NYSE: T) were moving higher today as CFO Pascal Desroches made comments at an investor conference reaffirming the company's free-cash-flow guidance and tamped down concerns about the

2 Top Growth Stocks to Buy With $500: https://g.foolcdn.com/editorial/images/747172/physician-giving-a-high-five-to-a-young-patient.jpg
2 Top Growth Stocks to Buy With $500

When investing in equities, even a relatively modest initial sum such as $500 can go a long way, provided investors pick the right stocks and continue adding to their positions regularly. Let's

Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/747177/a-couple-counting-money.jpg
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows: https://g.foolcdn.com/editorial/images/747180/a-person-counting-money-in-their-living-room.jpg
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows

Do you want to lock in a high-yielding dividend stock? You might consider those that are struggling and near their 52-week lows. While stock prices typically drop because of problems with the

This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now: https://g.foolcdn.com/editorial/images/746947/doctor-vaccinating-a-patient.jpg
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now

Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the

Better Bull Market Buy: CRISPR vs. Medtronic Stock: https://g.foolcdn.com/editorial/images/747379/gettyimages-1172040755.jpg
Better Bull Market Buy: CRISPR vs. Medtronic Stock

The market hasn't yet entered bull territory, but it's getting close. The S&P 500 already rose more than 20% from its bear market low -- now, it just has to reach a new high, and the next bull

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Novavax Is a Step Behind, Again. Should You Be Worried?: https://g.foolcdn.com/editorial/images/747521/gettyimages-1295271909.jpg
Novavax Is a Step Behind, Again. Should You Be Worried?

In the earliest days of the coronavirus vaccine race, Novavax (NASDAQ: NVAX) stood out as a potential winner. As a result, investors bet on the company and drove up its share price more than 2,700%

AEVIS VICTORIA SA – Publication of the half-year report 2023http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Publication of the half-year report 2023
AEVIS VICTORIA SA – Publication of the half-year report 2023
2 Top Dividend Stocks to Buy in September: https://g.foolcdn.com/editorial/images/747174/dividends.jpg
2 Top Dividend Stocks to Buy in September

If you're looking for dividend stocks that can provide steady income and growth potential, you might want to consider adding Amgen (NASDAQ: AMGN) and American Express (NYSE: AXP) to your portfolio

Up 20% in 1 Month, Is This Stock a Buy?: https://g.foolcdn.com/editorial/images/746814/nurse-vaccinating-elderly-patient.jpg
Up 20% in 1 Month, Is This Stock a Buy?

The pandemic isn't over -- much as we might wish it were. An ongoing surge in coronavirus cases is pouring cold water on these hopes. We recently got a stark reminder that the disease spares nobody

2 Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/746773/physician-talking-to-patient.jpg
2 Dividend Stocks to Buy and Hold Forever

Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown

2 Undervalued Dividend Stocks to Buy Now: https://g.foolcdn.com/editorial/images/747386/biotech.jpg
2 Undervalued Dividend Stocks to Buy Now

If you're looking for dividend stocks that offer both attractive yields and strong growth prospects, you might want to consider AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Both of

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday: https://g.foolcdn.com/editorial/images/747467/medical-professional-holding-dollar-sign-paperweight.jpg
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday

The hot-streak biotech stock of the moment, CymaBay Therapeutics (NASDAQ: CBAY), again rose in price on Tuesday. That extends the company's winning streak on the market following the impressive

EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Is Abbott Laboratories a Buy?: https://g.foolcdn.com/editorial/images/746749/doctors-talking-to-businessmen-on-a-meeting-in-hospital.jpg
Is Abbott Laboratories a Buy?

Despite its formidable market capitalization of $174 billion and more than 100 years in operation, Abbott Laboratories (NYSE: ABT) is a stock that can sometimes be overlooked. It doesn't make

2 No-Brainer Biotech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/747242/older-woman-laptop.jpg
2 No-Brainer Biotech Stocks to Buy Right Now

Biotech stocks are a great way to grow your portfolio over time -- you can get in early on an innovator and benefit as it brings exciting candidates through the pipeline to commercialization. Of